XORTX Commences Gout Program NDA Discussions with the FDA – Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA
XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces that it has submitted a Type C meeting request with the US Food and Drug Administration…